MedTrace Logo

Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

NCT07009600 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2025-06-06

No results posted yet for this study

Summary

In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node \[LN\]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).

Conditions

  • Gastric Cancer Stage IV

Interventions

DRUG

immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07009600 on ClinicalTrials.gov